價(jià)格 | ¥355 | ¥539 | ¥925 |
包裝 | 10mg | 25mg | 50mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-02 |
中文名稱:阿利克侖半富馬酸鹽 | 英文名稱:Aliskiren hemifumarate |
CAS:173334-58-2 | 品牌: TargetMol |
產(chǎn)地: 美國(guó) | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.7% | 產(chǎn)品類別: 抑制劑 |
貨號(hào): T1520 |
名稱 | Aliskiren hemifumarate |
描述 | Aliskiren hemifumarate (CGP60536B) is an orally active nonpeptide renin inhibitor with antihypertensive activity. |
激酶實(shí)驗(yàn) | Radioligand Binding Assay: Human CB1 and CB2 stably transfect HEK 293 cells and cell membrane is purified. 0.2-8 μg of the purified membrane is incubated with 0.75 nM [3H] CP55,940 and Rimonabant in the incubation buffer (50 mM Tris-HCl, 5 mM MgCl2, 1 mM EDTA, 0.3%BSA, pH 7.4). The non-specific binding is defined in the presence of 1 μM of CP55,940. The reactions are incubated for one and a half hours at 30 °C in Multiscreen. The reactions are terminated by manifold filtration and washed four times with ice-cold wash buffer (50 mM Tris, pH 7.4, 0.25% BSA).The radioactivity bound to the filters is measured by Topcount. The IC50 is determined as the concentration of Rimonabant required to inhibit 50% of the binding of [3H] CP55,940 and calculated by non-linear regression. |
體外活性 | Aliskiren hemifumarate appears to bind to both the hydrophobic S1/S3-binding pocket and to a large, distinct subpocket that extends from the S3-binding site towards the hydrophobic core of renin. Oral bioavailability of Aliskiren hemifumarate is 2.4% in rats, 16% in marmosets and about 2.5% in humans. [2] |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 93 mg/mL (76.3 mM) H2O : 92 mg/mL (75.4 mM) Ethanol : 93 mg/mL (76.3 mM) |
關(guān)鍵字 | Aliskiren hemifumarate | Aliskiren | SPP 100 hemifumarate | CGP60536B hemifumarate | cardiovascular diseases | SPP-100 | colon carcinoma | cachexia | cancer | Autophagy | CGP 60536 hemifumarate | Aliskiren Hemifumarate | Renin | inhibit | Hypertension | C26 | SPP100 | CGP60536 | CGP-60536 | Inhibitor |
相關(guān)產(chǎn)品 | Guanidine hydrochloride | Naringin | Valproic Acid | Taurine | Gefitinib | Aceglutamide | Captopril | Hydroxychloroquine | Curcumin | Stavudine | Paeonol | Sodium 4-phenylbutyrate |
相關(guān)庫(kù) | 抗癌上市藥物庫(kù) | 經(jīng)典已知活性庫(kù) | 抗癌化合物庫(kù) | 已知活性化合物庫(kù) | FDA 上市藥物庫(kù) | 臨床期小分子藥物庫(kù) | 藥物功能重定位化合物庫(kù) | 抗代謝疾病化合物庫(kù) | 抗癌臨床化合物庫(kù) | 抗癌藥物庫(kù) |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 566.2651萬(wàn)人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 化學(xué)試劑,生物活性小分子 | 經(jīng)營(yíng)模式 | 貿(mào)易,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP6年
|
河南威梯希化工科技有限公司
|
2025-01-23 | |
¥11 |
VIP1年
|
歐利希(上海)醫(yī)藥科技有限公司
|
2025-01-21 | |
¥126.90 |
VIP13年
|
上海阿拉丁生化科技股份有限公司
|
2025-01-20 | |
詢價(jià) |
VIP4年
|
湖北辰心藥業(yè)有限公司
|
2025-01-03 | |
詢價(jià) |
VIP7年
|
湖北帝柏化工有限公司
|
2024-12-19 | |
詢價(jià) |
VIP5年
|
陜西締都醫(yī)藥化工有限公司
|
2024-12-18 | |
¥588.90 |
VIP2年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 | |
詢價(jià) |
湖北諾迪納生物技術(shù)有限公司
|
2024-07-28 | ||
詢價(jià) |
VIP4年
|
湖北辰心藥業(yè)有限公司
|
2024-05-23 | |
詢價(jià) |
河北茹麒科技有限公司
|
2023-06-27 |